Clinical trial
Efficacy and Safety Study of Mepolizumab in Subjects With Severe…
NCT02836496 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT02836496 |
|---|---|
| Title | Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) |
| Official title | Study 200622: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Adolescent and Adult Subjects With Severe Hypereosinophilic Syndrome |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypereosinophilic Syndrome |
| Intervention type | Drug |
| Interventions | Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules |
| Enrollment | 108 |
| Start date | Mar 7, 2017 |
| Primary completion | Aug 8, 2019 |
| Completion | Aug 8, 2019 |
| First posted | Jul 19, 2016 |
| Last update posted | Feb 21, 2020 |
| Countries | Argentina, Belgium, Brazil, France, Germany, Italy, Mexico, Poland, Romania, Russia, Spain, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: